Neurocrine Biosciences Welcomes Dr. Sanjay Keswani as New Chief Medical Officer

Neurocrine Biosciences, Inc., a prominent player in the pharmacological field focused on neuroscience, has made a strategic move by appointing Dr. Sanjay Keswani as its Chief Medical Officer (CMO), effective June 2, 2025. This move is indicative of the company's aim to enhance its clinical and medical capabilities as it embarks on a new phase of growth.

Dr. Keswani is not new to the industry; he comes with a wealth of experience spanning over 20 years. His substantial background not only positions him as a leader in clinical development and medical affairs but also enriches Neurocrine's executive management team with his extensive expertise in multiple therapeutic areas. Prior to joining Neurocrine, Dr. Keswani served as the President and CEO of ImmunoBrain, a clinical-stage biotechnology company dedicated to leveraging neuroimmune communication for brain repair in neurodegenerative diseases.

In his words, Dr. Keswani expressed his excitement about joining Neurocrine at a critical juncture in the company's evolution. He emphasized the organization's commitment to research and development (R&D) aimed at creating essential treatments through various modes of action. This includes small molecules, peptide therapies, antibody treatments, and gene therapies.

Kyle W. Gano, the CEO of Neurocrine, highlighted the importance of Dr. Keswani’s role, stating, "Sanjay brings a wealth of strategic and development expertise to our team, enhancing our capabilities as we enter an exciting and pivotal time for the company." His involvement is expected to support Neurocrine's focus on expanding its reach beyond traditional small molecule therapies and into more cutting-edge treatment modalities.

Dr. Keswani's prior achievements in the pharmaceutical sector are notable. He played a vital role in the development of several first-in-class and best-in-class medications and held senior positions at major pharmaceutical companies, including Hoffman La Roche and Bristol-Myers Squibb. In these roles, he was responsible for overseeing research and development in areas such as neuroscience, ophthalmology, and rare diseases.

With a distinguished academic background, Dr. Keswani is an elected Fellow of the Royal College of Physicians in the UK. He also mentored students as a faculty member of the Neurology Department at The Johns Hopkins Hospital and established a research lab focused on neuroimmunology, which aimed at discovering treatments for neurodegeneration.

During Dr. Eiry W. Roberts' seven-year tenure as CMO, she successfully led expansion initiatives for products like INGREZZA®, along with notable advancements in the crinecerfont project, which gained FDA approval. Neurocrine intends to maintain the momentum created by Dr. Roberts as she transitions to a strategic advisory role within the company. CEO Kyle W. Gano acknowledged her invaluable contributions, remarking on her ability to build a formidable clinical development team and broaden the company's internal capabilities, which have become a competitive advantage as they navigate through this pivotal growth phase.

Neurocrine Biosciences has dedicated its efforts to developing life-changing treatments for patients suffering from various neurological, neuroendocrine, and neuropsychiatric disorders. Their portfolio showcases FDA-approved medications that target conditions such as tardive dyskinesia and Huntington's disease, and they continue to expand their pipeline with innovative compounds in various stages of clinical development.

For three decades, the company has remained steadfast in its mission, driven by a commitment to discovering and developing necessary treatments for under-addressed medical conditions. As Dr. Keswani steps into his new role, the leadership team at Neurocrine is poised to capitalize on his expertise to further its mission of relieving patient suffering through technological advancements in pharmaceuticals.

For more information, you can visit the official Neurocrine Biosciences website and follow them on various social platforms to stay updated on their developments and initiatives.